Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05644977 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT05644977 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 17 participants.
The verdict
NCT05644977, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.
Interventions
- DRUG Placebo
- DRUG Emraclidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-12-02 |
| Est. Completion | 2025-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05644977
The ClinicalTrials.gov registry entry for NCT05644977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05644977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05644977 about?
NCT05644977 is a clinical study titled "A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease". The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.
What is the current status of trial NCT05644977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2022-12-02. Estimated completion is 2025-04-14.
What interventions are being tested in trial NCT05644977?
The interventions under investigation include: Placebo (DRUG), Emraclidine (DRUG).
Who is sponsoring clinical trial NCT05644977?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.